Journal
NATURE COMMUNICATIONS
Volume 11, Issue 1, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-020-15892-8
Keywords
-
Categories
Funding
- National Institutes of Health [DP2HL137167, P01HL131471, UG3HL147367]
- American Cancer Society [129056-RSG-16-093]
- Lung Cancer Research Foundation
- Cystic Fibrosis Foundation
- DARPA [HR0011-17-2-0049]
- U.S. NIH [RM1 HG009490, R01 EB022376, U01 AI142756, R35 GM118062]
- HHMI
- Marble Center for Cancer Nanomedicine
- National Cancer Institute [P30-CA14051]
- Helen Hay Whitney Fellowship
- China Scholarship Council
Ask authors/readers for more resources
CRISPR-Cas9-associated base editing is a promising tool to correct pathogenic single nucleotide mutations in research or therapeutic settings. Efficient base editing requires cellular exposure to levels of base editors that can be difficult to attain in hard-to-transfect cells or in vivo. Here we engineer a chemically modified mRNA-encoded adenine base editor that mediates robust editing at various cellular genomic sites together with moderately modified guide RNA, and show its therapeutic potential in correcting pathogenic single nucleotide mutations in cell and animal models of diseases. The optimized chemical modifications of adenine base editor mRNA and guide RNA expand the applicability of CRISPR-associated gene editing tools in vitro and in vivo. Cas9 base editors are promising tools for correcting pathogenic single nucleotide mutations. Here the authors chemically modify mRNA encoding the editor and the gRNA to enhance editing and broaden its application.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available